Merus (MRUS) Stock Price
Merus Price
Revenue has compounded at 45.6% per year over the past 11 years to 34.88 M USD. Merus's net margin stands at -595.9%, down from -285.6% several years earlier. Analysts set a median price target of 98.94 USD, implying 9.9% above the current price. Of 23 analysts, 9 rate the stock a buy — an overall Hold consensus. The stock trades about 42% above its 52-week low.
Merus stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Merus over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Merus stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Merus's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Merus Price |
|---|---|
| 12/29/2025 | 90.00 USD |
| 12/26/2025 | 96.92 USD |
| 12/24/2025 | 96.91 USD |
| 12/23/2025 | 96.90 USD |
| 12/22/2025 | 96.95 USD |
| 12/19/2025 | 97.01 USD |
| 12/18/2025 | 96.80 USD |
| 12/17/2025 | 96.89 USD |
| 12/16/2025 | 96.92 USD |
| 12/15/2025 | 96.82 USD |
| 12/12/2025 | 96.93 USD |
| 12/11/2025 | 96.63 USD |
| 12/10/2025 | 96.77 USD |
| 12/9/2025 | 96.36 USD |
| 12/8/2025 | 96.27 USD |
| 12/5/2025 | 96.14 USD |
| 12/4/2025 | 96.22 USD |
| 12/3/2025 | 96.12 USD |
| 12/2/2025 | 95.99 USD |
| 12/1/2025 | 95.94 USD |
| 11/28/2025 | 96.14 USD |
| 11/26/2025 | 96.09 USD |
| 11/25/2025 | 96.02 USD |
| 11/24/2025 | 95.95 USD |
| 11/21/2025 | 95.76 USD |
| 11/20/2025 | 95.98 USD |
| 11/19/2025 | 96.04 USD |
| 11/18/2025 | 95.80 USD |
| 11/17/2025 | 95.88 USD |
| 11/14/2025 | 95.95 USD |
| 11/13/2025 | 96.08 USD |
| 11/12/2025 | 96.04 USD |
| 11/11/2025 | 95.48 USD |
| 11/10/2025 | 95.42 USD |
| 11/7/2025 | 95.23 USD |
| 11/6/2025 | 95.16 USD |
| 11/5/2025 | 95.18 USD |
| 11/4/2025 | 95.04 USD |
| 11/3/2025 | 94.78 USD |
| 10/31/2025 | 94.86 USD |
| 10/30/2025 | 95.06 USD |
| 10/29/2025 | 94.81 USD |
| 10/28/2025 | 94.90 USD |
| 10/27/2025 | 94.60 USD |
| 10/23/2025 | 94.42 USD |
| 10/22/2025 | 94.40 USD |
| 10/21/2025 | 94.60 USD |
| 10/20/2025 | 94.44 USD |
| 10/16/2025 | 94.88 USD |
| 10/15/2025 | 94.95 USD |
| 10/14/2025 | 94.83 USD |
| 10/13/2025 | 94.85 USD |
| 10/9/2025 | 94.58 USD |
| 10/8/2025 | 94.38 USD |
| 10/7/2025 | 94.39 USD |
| 10/6/2025 | 94.27 USD |
| 10/2/2025 | 94.15 USD |
| 10/1/2025 | 94.15 USD |
| 9/30/2025 | 94.15 USD |
| 9/29/2025 | 93.67 USD |
| 9/25/2025 | 68.10 USD |
| 9/24/2025 | 68.25 USD |
| 9/23/2025 | 68.22 USD |
| 9/22/2025 | 69.19 USD |
| 9/18/2025 | 68.95 USD |
| 9/17/2025 | 68.18 USD |
| 9/16/2025 | 66.90 USD |
| 9/15/2025 | 68.09 USD |
| 9/11/2025 | 69.80 USD |
| 9/10/2025 | 67.13 USD |
| 9/9/2025 | 68.55 USD |
| 9/8/2025 | 67.19 USD |
| 9/4/2025 | 66.23 USD |
| 9/3/2025 | 66.62 USD |
| 9/2/2025 | 66.30 USD |
| 8/28/2025 | 66.10 USD |
| 8/27/2025 | 67.28 USD |
| 8/26/2025 | 66.86 USD |
| 8/25/2025 | 65.74 USD |
| 8/21/2025 | 66.65 USD |
| 8/20/2025 | 64.43 USD |
| 8/19/2025 | 63.65 USD |
| 8/18/2025 | 66.00 USD |
| 8/14/2025 | 66.94 USD |
| 8/13/2025 | 67.09 USD |
| 8/12/2025 | 63.77 USD |
| 8/11/2025 | 64.60 USD |
| 8/7/2025 | 63.39 USD |
| 8/6/2025 | 65.54 USD |
Merus Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Merus Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | 0.02 | 0.03 | 0.03 | 0.02 | 0.04 | 0.04 | 0.04 | 0.03 | 0.06 | 0.04 | 0.19 | 0.59 | 1.22 |
| – | – | 100.00 | 950.00 | 57.14 | -18.18 | -11.11 | 79.17 | -11.63 | 2.63 | -12.82 | 61.76 | -23.64 | 347.62 | 212.77 | 108.16 |
| -1,000.00 | -1,400.00 | -750.00 | -57.14 | -42.42 | -77.78 | -133.33 | -100.00 | 73.68 | 74.36 | 35.29 | 35.29 | 35.29 | 35.29 | 35.29 | 35.29 |
| -10.00 | -14.00 | -15.00 | -12.00 | -14.00 | -21.00 | -32.00 | -43.00 | 28.00 | 29.00 | 12.00 | 19.41 | 14.82 | 66.35 | 207.53 | 432.00 |
| -0.02 | -0.02 | -0.03 | -0.05 | -0.04 | -0.05 | -0.06 | -0.08 | -0.15 | -0.14 | -0.26 | -0.05 | -0.05 | -0.19 | -0.59 | -1.22 |
| -1,700.00 | -2,300.00 | -1,300.00 | -247.62 | -118.18 | -192.59 | -258.33 | -183.72 | -392.11 | -361.54 | -770.59 | -96.36 | -116.67 | -100.00 | -100.00 | -100.00 |
| -17.00 | -23.00 | -47.00 | -64.00 | -24.00 | -49.00 | -70.00 | -58.00 | -122.00 | -140.00 | -207.00 | -438.00 | -389.00 | -283.00 | 13.00 | 406.00 |
| 88.89 | 35.29 | 104.35 | 36.17 | -62.50 | 104.17 | 42.86 | -17.14 | 110.34 | 14.75 | 47.86 | 111.59 | -11.19 | -27.25 | -104.59 | 3,023.08 |
| 9.04 | 14.82 | 15.89 | 20.09 | 22.83 | 23.40 | 29.06 | 40.61 | 46.31 | 57.83 | 68.83 | 68.83 | 68.83 | 68.83 | 68.83 | 68.83 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Merus generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Merus retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Merus's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Merus has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Merus's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Merus stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Merus Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Merus business model & stock analysis
Merus SWOT Analysis
Strengths
Merus NV has several strengths that give it a competitive advantage in the market. These strengths include:
- Advanced technology and expertise in bispecific antibody development
- Diverse portfolio of intellectual property rights and patents
- Strong financial position and revenue growth
- Experienced and knowledgeable management team
- Strong industry partnerships and collaborations
Weaknesses
Despite its strengths, Merus NV also faces certain weaknesses that may hinder its growth and performance. These weaknesses include:
- Dependence on a limited number of key customers for a significant portion of revenue
- Relatively small market share compared to larger competitors
- Potential vulnerability to changes in government regulations and healthcare policies
- High research and development costs
Opportunities
Merus NV has several opportunities to capitalize on in the market. These opportunities include:
- Increasing demand for targeted cancer therapies
- Growing biopharmaceutical market globally
- Potential for strategic partnerships and collaborations to expand product pipeline
- Emerging markets and untapped geographical regions
Threats
However, several threats can pose challenges to Merus NV's growth and success. These threats include:
- Intense competition in the biotechnology and biopharmaceutical industry
- Potential for regulatory hurdles and delays in product approvals
- Uncertainty in healthcare reimbursement landscape
- Risk of intellectual property infringement by competitors
Merus Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Merus Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Merus historical P/E ratio, EBIT multiple, and P/S ratio
Merus annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Merus shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Merus forecasts and price targets in August 2026
Analyst Price Targets 2026Merus Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 10/6/2025 | Downgrade | OutperformMarket Perform | – | |
| 9/30/2025 | Downgrade | OverweightEqual Weight | 56 | |
| 9/30/2025 | Downgrade | BuyNeutral | 51 | |
| 9/30/2025 | Downgrade | OutperformMarket Perform | – | |
| 9/30/2025 | Downgrade | BuyNeutral | – | |
| 9/30/2025 | Downgrade | BuyNeutral | 30 | |
| 9/30/2025 | Downgrade | BuyHold | 59 | |
| 9/30/2025 | Downgrade | OverweightEqual Weight | 33 | |
| 9/29/2025 | Downgrade | OverweightEqual Weight | 56 | |
| 9/29/2025 | Downgrade | BuyHold | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Merus Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/3/2026 | -1.40USD | - | 10.78 MUSD | - | 2026 Q2 |
| 5/5/2026 | -1.42USD | - | 11.07 MUSD | - | 2026 Q1 |
| 2/25/2026 | -1.22USD | - | 8.30 MUSD | - | 2025 Q4 |
| 5/2/2024 | -0.72USD | - | 10.36 MUSD | - | 2024 Q1 |
| 2/26/2024 | -0.72USD | - | 11.52 MUSD | - | 2023 Q4 |
| 8/7/2023 | -0.90USD | - | 11.05 MUSD | - | 2023 Q2 |
| 5/8/2023 | -0.90USD | - | 10.68 MUSD | - | 2023 Q1 |
| 2/27/2023 | -0.85USD | - | 9.85 MUSD | - | 2022 Q4 |
| 11/3/2022 | -0.64USD | - | 11.16 MUSD | - | 2022 Q3 |
| 8/8/2022 | -0.63USD | - | 10.55 MUSD | - | 2022 Q2 |
Merus shareholder structure
| % | Name |
|---|---|
8.19722% | |
5.64529% | |
5.27430% | |
4.91328% | |
4.64733% | |
4.46226% |
Merus Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
9.99% | SEC ↗ | |
9.60% | SEC ↗ | |
9.60% | SEC ↗ | |
8.80% | SEC ↗ | |
8.51% | SEC ↗ | |
8.51% | SEC ↗ | |
8.51% | SEC ↗ |
Merus Executives and Management Board
12 members · avg. age 56 · 17 % women
Dr. Sven Lundberg (60)
President, Chief Executive Officer, Executive Director · since 2019
5.74 M USD
Management
Mr. Peter Silverman (45)
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Mr. Gregory Perry (63)
Chief Financial Officer · since 2016
Dr. Fabian Zohren (48)
Chief Medical Officer
Ms. Sherri Spear
Investor Relations and Corporate Communications · since 2022
Board of Directors
Dr. Anand Mehra (48)
Non-Executive Independent Chairman of the Board
Mr. Mark Iwicki (57)
Non-Executive Independent Director · since 2018
Dr. Victor Sandor (57)
Non-Executive Independent Director
Dr. Maxine Gowen (65)
Non-Executive Independent Director
Mr. Paolo Pucci (61)
Non-Executive Independent Director
Mr. Leonard Kanavy (61)
Non-Executive Independent Director
Merus Supply Chain
Merus Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.36 | 0.02 | 0.71 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Sema4 Holdings A | 0.73 | -0.30 | — | |
| 2 | -0.15 | -0.45 | -0.67 | ||
| 3 | 0.69 | -0.05 | -0.55 | ||
| 4 | -0.72 | -0.17 | -0.52 |
Frequently asked questions about Merus
The business model of Merus NV focuses on developing innovative bispecific antibody therapeutics to treat various types of cancer. By utilizing its proprietary technology platform, Merus aims to design and develop bispecific antibodies that can simultaneously target and bind to multiple cancer cell targets. This unique approach has the potential to enhance the efficacy and safety profile of cancer treatments. Merus collaborates with pharmaceutical companies to advance its pipeline candidates, while also retaining rights to develop and commercialize certain product candidates. Through its research and development efforts, Merus NV strives to provide groundbreaking solutions for patients suffering from cancer-related diseases.
Merus NV is primarily active in the biotechnology industry.
The main competitors of Merus NV in the market include biotechnology companies such as Regeneron Pharmaceuticals, Inc., Amgen Inc., Genmab A/S, and Roche Holding AG. These companies operate in similar therapeutic areas, developing innovative antibody-based therapeutics and immuno-oncology treatments, potentially competing with Merus NV's pipeline. It is important for investors and market participants to closely monitor the competitive landscape as it can impact Merus NV's market share, product development, and financial performance.
Merus NV is a biotechnology company based in the Netherlands. Founded in 2003, the company specializes in developing innovative bispecific antibody therapeutics for the treatment of cancer. Merus NV has a unique approach to target tumor cells directly while minimizing side effects. The company has a strong pipeline of candidates, including MCLA-128, MCLA-117, and MCLA-158, targeting various types of cancers. With collaborations and partnerships with renowned pharmaceutical companies, Merus NV aims to advance the field of antibody therapeutics and make a lasting impact on patient care. Throughout its history, Merus NV has achieved significant milestones in drug discovery and clinical development, positioning itself as a key player in the biotechnology industry.
Merus NV, a leading biotechnology company, has achieved several significant milestones. The company successfully initiated multiple clinical trials, including ongoing studies for its innovative bispecific antibody programs. Merus NV also secured strategic collaborations with renowned pharmaceutical companies, further validating its cutting-edge technology and expanding its market reach. In addition, Merus NV has received regulatory approvals for its investigational therapies, paving the way for potential commercialization. These achievements demonstrate the company's strong commitment to advancing its pipeline and driving growth. Merus NV's dedication to scientific excellence and continuous innovation positions it as a formidable player in the biotech industry.
Merus NV is primarily present in the Netherlands and the United States.
Merus NV represents values such as innovation, collaboration, and patient-centricity. With a commitment to advancing bispecific antibody therapeutics, Merus NV aims to improve patient outcomes and address unmet medical needs. The company's corporate philosophy is based on fostering scientific excellence and leveraging its core technologies to develop transformative medicines. Merus NV embraces a culture of integrity, diversity, and teamwork, driving its pursuit of novel solutions in the field of oncology. By integrating its unique approach with strategic partnerships, Merus NV strives to deliver breakthrough treatments for patients.
Analysts currently set an average price target of 99.48 USD for the Merus stock (median: 98.94 USD), implying +10.5 % versus the latest price. The consensus is based on 23 analyst ratings.
23 analysts currently rate the Merus stock: 9 recommend buying, 14 holding and 0 selling. For 2026, analysts expect Merus to generate revenue of 42.47 M USD and earnings per share of -5.66 USD.
Converted at the current exchange rate, the Merus share trades at 78.09 EUR (90.00 USD).
The Merus share (MRUS) is listed on 3 stock exchanges, including: NASDAQ (MRUS), Frankfurt (2GH.F), München (2GH.MU).
Merus NV is a biotechnology company specializing in the development of bispecific antibodies for the treatment of cancer. The company's business model is based on the research, development, and commercialization of novel therapies to combat cancer. Merus NV has three main business areas and develops products in each of these categories: therapeutic products, diagnostics, and research. The company's therapeutic products utilize bispecific antibodies (Biclonics®) that combine the properties of two different antibodies, resulting in greater specificity, higher efficacy, and reduced toxicity. Merus NV is building a pipeline of bispecific antibodies targeting a variety of cancer types. Currently, the company has three products in clinical development: MeMo, MCLA-128, and MCLA-117. Merus NV collaborates closely with renowned pharmaceutical companies such as Incyte and DSM Biomedical in the development of cancer immunotherapies. In the diagnostics product line, Merus NV offers a technology platform that enables the development of diagnostic tests for therapeutic products and supports biomarker research. The company is also involved in the development of antibody imaging tools, serving an important role in toxic analysis and biomarker-driven clinical studies. Finally, Merus NV's research department supports its own development activities as well as those of external parties through collaborations and alliances. In summary, Merus NV's business model is based on the development, commercialization, and marketing of bispecific antibodies to combat cancer. With innovative solutions and technologies in the field of diagnostic tests and therapy monitoring, the company has distinct competitive advantages and can meet the demands of customers and partners. Merus NV is a leading company in the field of bispecific antibody technology and offers a diverse product pipeline to meet the demanding requirements of the entire cancer market.
The expected revenue of Merus is 42.47 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Merus is -389.54 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Merus is currently -15.90. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Merus stock.
The price-to-sales ratio (P/S) of Merus is currently 145.86. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Merus stock.
The Eulerpool Quality Score for Merus is 3/10.
The ISIN of Merus is NL0011606264. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Merus is A2AKFX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Merus is MRUS. The ticker symbol is used to trade Merus shares on the stock exchange.
Merus paid dividends every year for the past 0 years.
Merus is assigned to the 'Health' sector.
The dividends of Merus are distributed in USD.
Merus stock
Merus Peer Group
Merus Ticker
Merus FIGI
All fundamentals and in-depth analysis of Merus
Our stock analysis for Merus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.